S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
NASDAQ:PCRX

Pacira BioSciences Stock Forecast, Price & News

$63.43
-0.57 (-0.89%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$63.31
$66.11
50-Day Range
$51.11
$64.26
52-Week Range
$45.05
$80.00
Volume
499,946 shs
Average Volume
495,525 shs
Market Capitalization
$2.83 billion
P/E Ratio
46.64
Dividend Yield
N/A
Beta
1
30 days | 90 days | 365 days | Advanced Chart
Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.


Pacira BioSciences logo

About Pacira BioSciences

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Headlines

Hedge Funds Are Crazy About Pacira Biosciences Inc (PCRX)
December 11, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PCRX
CUSIP
69512710
Employees
624
Year Founded
N/A

Sales & Book Value

Annual Sales
$429.65 million
Cash Flow
$2.21 per share
Book Value
$14.26 per share

Profitability

Net Income
$145.52 million
Pretax Margin
14.67%

Debt

Price-To-Earnings

Miscellaneous

Free Float
42,228,000
Market Cap
$2.83 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
1/21/2022
Next Earnings (Estimated)
2/24/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.17 out of 5 stars

Medical Sector

621st out of 1,418 stocks

Pharmaceutical Preparations Industry

298th out of 683 stocks

Analyst Opinion: 3.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -












Pacira BioSciences (NASDAQ:PCRX) Frequently Asked Questions

Is Pacira BioSciences a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Pacira BioSciences stock.
View analyst ratings for Pacira BioSciences
or view top-rated stocks.

How has Pacira BioSciences' stock price been impacted by Coronavirus (COVID-19)?

Pacira BioSciences' stock was trading at $35.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PCRX shares have increased by 80.3% and is now trading at $63.43.
View which stocks have been most impacted by COVID-19
.

When is Pacira BioSciences' next earnings date?

Pacira BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Pacira BioSciences
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) released its quarterly earnings results on Tuesday, November, 2nd. The company reported $0.72 EPS for the quarter, beating the Zacks' consensus estimate of $0.65 by $0.07. The company earned $127.70 million during the quarter, compared to analyst estimates of $129.69 million. Pacira BioSciences had a trailing twelve-month return on equity of 14.39% and a net margin of 12.01%. The firm's revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.43 EPS.
View Pacira BioSciences' earnings history
.

What price target have analysts set for PCRX?

9 Wall Street analysts have issued 1 year price targets for Pacira BioSciences' shares. Their forecasts range from $60.00 to $97.00. On average, they expect Pacira BioSciences' stock price to reach $81.67 in the next year. This suggests a possible upside of 28.8% from the stock's current price.
View analysts' price targets for Pacira BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Pacira BioSciences' key executives?

Pacira BioSciences' management team includes the following people:

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences CEO Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among Pacira BioSciences' employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (5.29%), Frontier Capital Management Co. LLC (2.09%), Stonnington Group LLC (0.72%), Tributary Capital Management LLC (0.40%), Gradient Investments LLC (0.31%) and Russell Investments Group Ltd. (0.29%). Company insiders that own Pacira BioSciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, David M Stack, Donald C Manning, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends for Pacira BioSciences
.

Which major investors are selling Pacira BioSciences stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Crossmark Global Holdings Inc., Scout Investments Inc., State of Alaska Department of Revenue, and First Hawaiian Bank. Company insiders that have sold Pacira BioSciences company stock in the last year include Andreas Wicki, Charles A Reinhart III, David M Stack, Donald C Manning, Kristen Marie Williams, Lauren Bullaro Riker, Max Reinhardt, and Roy Winston.
View insider buying and selling activity for Pacira BioSciences
or view top insider-selling stocks.

Which major investors are buying Pacira BioSciences stock?

PCRX stock was acquired by a variety of institutional investors in the last quarter, including Stonnington Group LLC, Baillie Gifford & Co., Frontier Capital Management Co. LLC, Russell Investments Group Ltd., Gradient Investments LLC, Next Capital Management LLC, Capital Insight Partners LLC, and Louisiana State Employees Retirement System.
View insider buying and selling activity for Pacira BioSciences
or or view top insider-buying stocks.

How do I buy shares of Pacira BioSciences?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $63.43.

How much money does Pacira BioSciences make?

Pacira BioSciences has a market capitalization of $2.83 billion and generates $429.65 million in revenue each year. The company earns $145.52 million in net income (profit) each year or $1.36 on an earnings per share basis.

How many employees does Pacira BioSciences have?

Pacira BioSciences employs 624 workers across the globe.

What is Pacira BioSciences' official website?

The official website for Pacira BioSciences is www.pacira.com.

Where are Pacira BioSciences' headquarters?

Pacira BioSciences is headquartered at 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at (813) 553-6680, via email at [email protected], or via fax at 302-655-5049.


This page was last updated on 1/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.